Trial
NCT01464359
T-Cell Depleted Double UCB for Refractory AML
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Acute Myelogenous Leukemia
Intervention
Allopurinol
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-28